The Influence of Sitagliptin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus Receiving Insulin Treatment: A Prespecified Sub-Analysis

[1]  8. Pharmacologic Approaches to Glycemic Treatment , 2016, Diabetes Care.

[2]  I. Shimomura,et al.  Sitagliptin Attenuates the Progression of Carotid Intima-Media Thickening in Insulin-Treated Patients With Type 2 Diabetes: The Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE) , 2016, Diabetes Care.

[3]  H. Itoh,et al.  Efficacy and Safety of Sitagliptin Added to Insulin in Japanese Patients with Type 2 Diabetes: The EDIT Randomized Trial , 2015, PloS one.

[4]  I. Shimomura,et al.  Rationale, design, and baseline characteristics of a clinical trial for prevention of atherosclerosis in patients with insulin-treated type 2 diabetes mellitus using DPP-4 inhibitor: the Sitagliptin Preventive study of Intima-media thickness Evaluation (SPIKE) , 2014, Diabetology & Metabolic Syndrome.

[5]  T. Kondo,et al.  Efficacy and safety of sitagliptin as add-on therapy on glycemic control and blood glucose fluctuation in Japanese type 2 diabetes subjects ongoing with multiple daily insulin injections therapy. , 2013, Endocrine journal.

[6]  M. Namba,et al.  Add-on therapy with the DPP-4 inhibitor sitagliptin improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus. , 2013, Endocrine journal.

[7]  J. Oyama,et al.  Effects of sitagliptin beyond glycemic control: focus on quality of life , 2013, Cardiovascular Diabetology.

[8]  H. Ishii Development and Psychometric validation of the Diabetes Therapy-Related QOL (DTR-QOL) Questionnaire , 2012, Journal of medical economics.

[9]  N. Tajima,et al.  Efficacy of combined use of miglitol in Type 2 diabetes patients receiving insulin therapy-placebo-controlled double-blind comparative study , 2011, Acta Diabetologica.

[10]  F. Camacho,et al.  Diabetes Medication Satisfaction Tool , 2009, Diabetes Care.

[11]  F. Camacho,et al.  The Diabetes Medication Satisfaction Tool (DMSAT): A Focus on Treatment Regimens , 2008 .

[12]  H. Ishii,et al.  Improvement of glycemic control and quality-of-life by insulin lispro therapy: Assessing benefits by ITR-QOL questionnaires. , 2008, Diabetes research and clinical practice.

[13]  B. Frier,et al.  Vascular disease and diabetes: is hypoglycaemia an aggravating factor? , 2008, Diabetes/metabolism research and reviews.

[14]  B. Adams-Huet,et al.  Weight gain in type 2 diabetes mellitus , 2007, Diabetes, obesity & metabolism.

[15]  B. Goldstein,et al.  Cardiovascular risk in the spectrum of type 2 diabetes mellitus. , 2006, The Mount Sinai journal of medicine, New York.

[16]  T. Yoshikawa,et al.  Efficacy of glimepiride in patients with poorly controlled insulin-treated type 2 diabetes mellitus. , 2005, Endocrine journal.

[17]  H. Bilo,et al.  Cross-sectional relationship between glycaemic control, hyperglycaemic symptoms and quality of life in type 2 diabetes (ZODIAC-2). , 2005, The Netherlands journal of medicine.

[18]  P. Raskin,et al.  Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes. , 2002, Diabetes care.

[19]  Kenzo Oba,et al.  [Treatment guide for diabetes]. , 2011, Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics.

[20]  J. Nunnally Psychometric Theory (2nd ed), New York: McGraw-Hill. , 1978 .